Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC15022 Vandetanib (ZD6474)

    ZD6474

     Vandetanib (ZD6474) (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib (ZD6474) also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM). Vandetanib (ZD6474) Chemical Structure
  3. GC11876 Vandetanib hydrochloride

    Zactima hydrochloride; ZD6474 hydrochloride;ZD-6474 hydrochloride; ZD 6474 hydrochloride

     A multi-kinase inhibitor Vandetanib hydrochloride Chemical Structure
  4. GC37886 Vandetanib trifluoroacetate Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM). Vandetanib trifluoroacetate Chemical Structure
  5. GC45769 Vandetanib-d6

    ZD6474-d6

     An internal standard for the quantification of vandetanib Vandetanib-d6 Chemical Structure
  6. GC70111 Vanucizumab

    Anti-Human VEGFA Recombinant Antibody; RO5520985

    Vanucizumab is a novel bispecific IgG1 monoclonal antibody that can simultaneously block the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their receptors. Vanucizumab has anti-angiogenic and anticancer effects.

     Vanucizumab Chemical Structure
  7. GC12249 Varlitinib (ARRY334543)

    ARRY-334543; ARRY 334543

     Varlitinib (ARRY334543) (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively. Varlitinib (ARRY334543) Chemical Structure
  8. GC14464 Vatalanib

    CGP-79787; PTK 787; ZK222584

     A potent and selective VEGF receptor inhibitor Vatalanib Chemical Structure
  9. GC17955 Vatalanib (PTK787) 2HCl

    CGP 79787, PTK787, PTK/ZK

     Vatalanib (PTK787) 2HCl (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM. Vatalanib (PTK787) 2HCl Chemical Structure
  10. GC50233 Vatalanib succinate Potent VEGFR inhibitor; also aromatase inhibitor Vatalanib succinate Chemical Structure
  11. GC34077 Vecabrutinib (SNS-062) Vecabrutinib (SNS-062) (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib (SNS-062) shows an IC50 of 24 nM for ITK. Vecabrutinib (SNS-062) Chemical Structure
  12. GC16062 VEGFR Tyrosine Kinase Inhibitor II

    Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II

     VEGFR Tyrosine Kinase Inhibitor II (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 μM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. VEGFR Tyrosine Kinase Inhibitor II Chemical Structure
  13. GC66043 VEGFR-2-IN-29 VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC50 of 16.5 nM. VEGFR-2-IN-29 Chemical Structure
  14. GC61600 VEGFR-2-IN-6 VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110. VEGFR-2-IN-6 Chemical Structure
  15. GC64205 VEGFR-3-IN-1 VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth. VEGFR-3-IN-1 Chemical Structure
  16. GC45142 VEGFR2 Kinase Inhibitor II Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. VEGFR2 Kinase Inhibitor II Chemical Structure
  17. GC68396 Vepafestinib Vepafestinib Chemical Structure
  18. GC31533 Vimirogant (VTP-43742) Vimirogant (VTP-43742) (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant (VTP-43742) Chemical Structure
  19. GC62103 Vodobatinib

    K0706

     Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research. Vodobatinib Chemical Structure
  20. GC70122 Vofatamab

    B-701; MFGR-1877S; RG-7444

    Vofatamab (B-701) is a monoclonal antibody (mAb) that targets FGFR3. Vofatamab blocks the activation of both wild-type and mutated receptors. It is being studied for its potential use in metastatic urothelial carcinoma (MUC).

     Vofatamab Chemical Structure
  21. GC38380 Vorolanib

    CM082; X-82

     Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib Chemical Structure
  22. GC70125 Vosoritide acetate

    BMN 111 acetate

    Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that can stimulate the proliferation and differentiation of chondrocytes, promoting bone growth.

     Vosoritide acetate Chemical Structure
  23. GC39301 VU6015929 VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with IC50s of 4.67 nM and 7.39 nM, respectively. VU6015929 Chemical Structure
  24. GC26063 WAY-340935

    VEGFR2-IN-2

     WAY-340935 (VEGFR2-IN-2) can inhibit the function of VEGFR2 and the anti-proliferative activity against the H460 cell line is produced partly by interaction of VEGFR protein. WAY-340935 Chemical Structure
  25. GC34110 WEHI-345 analog WEHI-345 analog is the analog of WEHI-345. WEHI-345 analog Chemical Structure
  26. GC13600 WH-4-023

    Dual LCK/SRC inhibitor

     Lck/Src inhibitor,potent and selective WH-4-023 Chemical Structure
  27. GC15589 WHI-P154

    JAK3 Inhibitor II, JanusAssociated Kinase 3 Inhibitor II

     A JAK3 inhibitor WHI-P154 Chemical Structure
  28. GC16000 WHI-P180

    Janex 3

     EGFR/Janus Kinase 3 inhibitor WHI-P180 Chemical Structure
  29. GC37933 WHI-P180 hydrochloride

    Janex 3 hydrochloride;

     WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride Chemical Structure
  30. GC10970 WP1130

    WP 1130; WP-1130

     WP1130 (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. WP1130 has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2. WP1130 Chemical Structure
  31. GC38206 WRG-28 WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 Chemical Structure
  32. GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible WZ3146 Chemical Structure
  33. GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent WZ4002 Chemical Structure
  34. GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent WZ8040 Chemical Structure
  35. GC19140 X-376 X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively. X-376 Chemical Structure
  36. GC70151 Xentuzumab

    BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

    Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant humanized monoclonal antibody that targets the IGF ligands IGF1 and IGF2. Xentuzumab inhibits the growth-promoting signals of both IGF1 and IGF2, suppressing the activation of AKT.

     Xentuzumab Chemical Structure
  37. GC62266 XL092

    XL092

     XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity. XL092 has the potential for kinase-dependent diseases and conditions research. XL092 Chemical Structure
  38. GC13102 XL228 A tyrosine kinase inhibitor XL228 Chemical Structure
  39. GC62146 XST-14 XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects. XST-14 Chemical Structure
  40. GC50389 XY 018 RORγ antagonist; inhibits AR expression XY 018 Chemical Structure
  41. GC37944 XY101 XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC50 of 30 nM and a Kd of 380 nM. XY101 Chemical Structure
  42. GC14489 Y 11

    FAK Inhibitor 10

    focal adhesion kinase (FAK) inhibitor

     Y 11 Chemical Structure
  43. GC64992 YH-306 YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization. YH-306 Chemical Structure
  44. GC10195 Z-Guggulsterone Z-Guggulsterone, a component of the Ayurvedic medicinal plant Commiphora mukul, suppresses angiogenesis in vitro and in vivo with IC50 values of 1740, 1000, 220 and > 50000 nM for glucocorticoid, mineralocorticoid, androgen and farnesoid X receptors. Z-Guggulsterone Chemical Structure
  45. GC63263 Zabedosertib

    BAY 1834845

     Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential. Zabedosertib Chemical Structure
  46. GC70164 Zalutumumab

    Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.

     Zalutumumab Chemical Structure
  47. GC70165 Zanidatamab

    ZW 25

    Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.

     Zanidatamab Chemical Structure
  48. GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer. ZD-4190 Chemical Structure
  49. GC70169 Zenocutuzumab

    MCLA-128; PB4188; R040517

    Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody that contains two different Fab arms targeting the extracellular domains of HER2 and HER3.

     Zenocutuzumab Chemical Structure
  50. GC64340 Zeteletinib

    BOS-172738; DS-5010

     Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity. Zeteletinib Chemical Structure
  51. GC66327 Zilovertamab

    UC-961; Cirmtuzumab

     Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. Zilovertamab Chemical Structure
  52. GC31816 ZK-261991 ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. ZK-261991 Chemical Structure
  53. GC12185 ZM 306416

    CB-676475

     VEGFR (Flt and KDR) inhibitor ZM 306416 Chemical Structure
  54. GC50028 ZM 306416 hydrochloride Inhibitor of VEGF receptor tyrosine kinase ZM 306416 hydrochloride Chemical Structure
  55. GC11555 ZM 323881 HCl ZM 323881 HCl is a potent and selective VEGFR2 inhibitor with an IC50 of less than 2 nM. ZM 323881 HCl Chemical Structure
  56. GC12656 ZM323881

    ZM 323881;ZM-323881

     A potent and selective VEGFR2 inhibitor ZM323881 Chemical Structure
  57. GC62112 Zotiraciclib Zotiraciclib Chemical Structure
  58. GC64013 ZX-29 ZX-29 is a potent and selective ALK inhibitor with an IC50 of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect. ZX-29 Chemical Structure

Items 1101 to 1157 of 1157 total

per page
  2. 8
  3. 9
  4. 10
  5. 11
  6. 12

Set Descending Direction